<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_gsckrPB">The impact of using reinforcement learning to personalize communication on medication adherence: findings from the REINFORCE trial Check for updates</title>
				<funder>
					<orgName type="full">National Institutes of Health</orgName>
					<orgName type="abbreviated">NIH</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000002</idno>
				</funder>
				<funder ref="#_BCJ46Zr #_9hvwH7p">
					<orgName type="full">National Institute on Aging of the National Institutes of Health</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Julie</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
							<email>jlauffenburger@bwh.harvard.edu</email>
							<idno type="ORCID">0000-0002-4940-4140</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elad</forename><surname>Yom-Tov</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Microsoft Research , Herzliya , Israel.</note>
								<orgName type="institution">Microsoft Research</orgName>
								<address>
									<settlement>Herzliya</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Punam</forename><forename type="middle">A</forename><surname>Keller</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Tuck School of Business , Dartmouth College , Hanover , NH , USA.</note>
								<orgName type="department">Tuck School of Business</orgName>
								<orgName type="institution">Dartmouth College</orgName>
								<address>
									<settlement>Hanover</settlement>
									<region>NH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie</forename><forename type="middle">E</forename><surname>Mcdonnell</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Division of Endocrinology, Diabetes and Hypertension , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Division of Endocrinology, Diabetes and Hypertension</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="department" key="dep3">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katherine</forename><forename type="middle">L</forename><surname>Crum</surname></persName>
							<idno type="ORCID">0000-0002-0074-0645</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gauri</forename><surname>Bhatkhande</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ellen</forename><forename type="middle">S</forename><surname>Sears</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kaitlin</forename><surname>Hanken</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lily</forename><forename type="middle">G</forename><surname>Bessette</surname></persName>
							<idno type="ORCID">0000-0003-1088-8579</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Constance</forename><forename type="middle">P</forename><surname>Fontanet</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nancy</forename><surname>Haff</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Seanna</forename><surname>Vine</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Niteesh</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Center for Healthcare Delivery Sciences , Division of Pharmacoepidemiology and Pharmacoeconomics , Department of Medicine , Brigham and Women&apos;s Hospital and Harvard Medical School , Boston , MA , USA.</note>
								<orgName type="department" key="dep1">Center for Healthcare Delivery Sciences</orgName>
								<orgName type="department" key="dep2">Division of Pharmacoepidemiology and Pharmacoeconomics</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">Brigham and Women&apos;s Hospital and Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_A9Jp23F">The impact of using reinforcement learning to personalize communication on medication adherence: findings from the REINFORCE trial Check for updates</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4581EED3427FF7111CBF924280390FD9</idno>
					<idno type="DOI">10.1038/s41746-024-01028-5</idno>
					<note type="submission">Received: 1 August 2023; Accepted: 5 February 2024;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T09:45+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_ThB4yn5"><p xml:id="_x3sqq5g"><s xml:id="_nHCSV3U">Text messaging can promote healthy behaviors, like adherence to medication, yet its effectiveness remains modest, in part because message content is rarely personalized.</s><s xml:id="_WmwgPRy">Reinforcement learning has been used in consumer technology to personalize content but with limited application in healthcare.</s><s xml:id="_eSEaKzM">We tested a reinforcement learning program that identifies individual responsiveness ("adherence") to text message content and personalizes messaging accordingly.</s><s xml:id="_WBUq84E">We randomized 60 individuals with diabetes and glycated hemoglobin A1c [HbA1c] ≥ 7.5% to reinforcement learning intervention or control (no messages).</s><s xml:id="_J3XEUEw">Both arms received electronic pill bottles to measure adherence.</s><s xml:id="_75jqsRW">The intervention improved absolute adjusted adherence by 13.6% (95%CI: 1.7%-27.1%)</s><s xml:id="_MEnryYk">versus control and was more effective in patients with HbA1c 7.5-&lt; 9.0% (36.6%, 95%CI: 25.1%-48.2%,</s><s xml:id="_SBG73dX">interaction p &lt; 0.001).</s><s xml:id="_vVah7tv">We also explored whether individual patient characteristics were associated with differential response to tested behavioral factors and unique clusters of responsiveness.</s><s xml:id="_j457XY4">Reinforcement learning may be a promising approach to improve adherence and personalize communication at scale.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_X4wjpTw"><p xml:id="_xh7B9jv"><s xml:id="_UbE6tT5">Text messages can be delivered at low cost and provide reminders, education, and motivational support for health behaviors on an ongoing basis <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_rDqCZ4E">They have demonstrated effectiveness for supporting physical activity, medication adherence, and other daily self-management activities that are guideline recommended for managing chronic diseases, like type 2 diabetes <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_XPC9Je5">However, many prior text messaging interventions have used generic message content (i.e., the same messages delivered to all patients) <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> .</s></p><p xml:id="_t77CZnG"><s xml:id="_fx8ukCq">Yet, a key principle for changing health behaviors is personalization and how information is presented to match an individual's specific needs, which may also change over time <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> .</s><s xml:id="_VnhH8Dd">Personalization can be based upon simple characteristics, such as name, age, or health metrics <ref type="bibr" target="#b10">11</ref> .</s><s xml:id="_24BVqfX">More detailed personalization could potentially be achieved by incorporating routines or behavioral barriers, and adjusting frequently <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref> .</s></p><p xml:id="_DRju3br"><s xml:id="_tzhRywV">A major obstacle to achieving personalization based on underlying behavioral tendencies is the ability to predict what patients will actually respond to.</s><s xml:id="_ce6ddQ7">Traditionally, theory-based assessments, or expert opinion (like barrier elicitation by clinicians), have been used to tailor behavioral messaging particularly at the outset, and sometimes, with updates at intervals <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> .</s><s xml:id="_dFycbv8">For example, the REACH trial used interactive texts that asked participants directly about their adherence through weekly feedback, and another recent trial used dynamic tailoring based on patients' implementation intention plan <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18</ref> .</s><s xml:id="_ZUMMfaa">An alternative approach is to use observations of what content patients actually respond to and use that as the basis for what they will respond to in the future.</s><s xml:id="_KcW4Tf4">This process is made feasible by mobile health tools (like electronic pill bottles) that passively measure health behaviors on an ongoing basis.</s><s xml:id="_7thR9qz">Consistent with this, there is emerging interest in just-in-time adaptive interventions (JITAIs), or an intervention design that adapts support (e.g., type, timing, intensity) over time in response to an individual's changing status and context <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> .</s></p><p xml:id="_CrETRRZ"><s xml:id="_TVRAJYK">An efficient approach to achieve such personalized intervention is with the use of reinforcement learning <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_cwk4q37">This machine learning method trains a statistical model based on rewards from actions of the model in an environment.</s><s xml:id="_rYKRYkM">In the context of behavior change, the model observes individual behaviors in response to cues it provides (like text messages) and learns to optimize response (like adherence) through systematic trial-and-error <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref> .</s><s xml:id="_WYFC97C">This technique has technological underpinnings applied in computer gaming and robotics <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref> .</s><s xml:id="_pNG8y5Y">In contrast to other approaches to achieving personalization, reinforcement learning uses approaches that predict the effectiveness of different intervention components and also can use latently derived estimates for tailoring (rather than end user input); and, as interventions are deployed, updates the predictions based on their successes and failures (both at the individual and group level) <ref type="bibr" target="#b27">28</ref> .</s><s xml:id="_aPfJgYA">That is, the algorithm "learns" to personalize as it experiments, or "adapts" <ref type="bibr" target="#b28">29</ref> .</s></p><p xml:id="_EGjHfQk"><s xml:id="_Vu9Y8jR">Reinforcement learning has thus far had limited use in health care <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref> and has not been applied to medication adherence, an essential daily activity for most patients with chronic disease, and especially diabetes, which affects 529 million individuals globally <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b32">33</ref> .</s><s xml:id="_jQavxcs">While machine learning generally has been shown to be helpful in measuring suboptimal adherence <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref> , there remains much opportunity to explore how it and related techniques can improve adherence.</s><s xml:id="_B5sCwVR">Accordingly, we launched the REinforcement learning to Improve Non-adherence For diabetes treatments by Optimizing Response and Customizing Engagement trial (REINFORCE) to evaluate the impact of a text messaging program tailored using reinforcement learning on medication adherence for patients with type 2 diabetes <ref type="bibr" target="#b21">22</ref> .</s></p><p xml:id="_Ywq5vQV"><s xml:id="_7ECHDNw">The trial design has been published <ref type="bibr" target="#b21">22</ref> with expanded details in the Methods.</s><s xml:id="_NtdrCSg">In brief, 60 patients with type 2 diabetes (with their latest glycated hemoglobin A1c [HbA1c] lab value ≥ 7.5% in the past 180 days) were randomized to a reinforcement learning intervention or control (no intervention) based on pre-specified power calculations.</s><s xml:id="_4j4Jkbn">In both arms, patients received a separate electronic pill bottle for each of their diabetes medications, with bottles that look like those dispensed by retail pharmacies but with an electronic cap that recorded the dates and times in which participants took their medications.</s><s xml:id="_BQEjNyJ">A figure of the infrastructure was previously published <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_4D2dqnH">The reinforcement learning algorithm personalized daily texts based on adherence, patient characteristics, and message history using the following 5 behavioral factors: (1) how the messages are structured ("Framing"; classified as neutral, positive [invoking positive outcomes of medication use], or negative [invoking consequences of medication nonuse]), (2) observed feedback ("History", i.e., including the number of days in the prior week the patient was adherent), (3) social reinforcement ("Social", i.e., referring to loved ones), (4) whether content was a reminder or informational ("Content"), and (5) whether the text included a reflective question ("Reflective").</s><s xml:id="_UTMJx64">Individual messages contained elements from these different factor sets, examples of which have been published previously <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_VURuHnJ">The primary outcome was average pill bottle-measured adherence over a 6-month follow-up.</s><s xml:id="_F4Mkg56">After trial completion, we described the performance of the reinforcement learning algorithm process itself and explored responsiveness to behavioral factors using subgroup analyses and clustering methods, as prior work has suggested that there may be important differences in responsiveness <ref type="bibr" target="#b23">24</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2r75AkC">Results</head><p xml:id="_EPgjFQz"><s xml:id="_PT6vXra">Among 60 patients, 29 and 31 were randomized to the intervention and control arms, respectively, of which 1 intervention and 3 control patients did not complete follow-up (Fig. <ref type="figure">1</ref>).</s><s xml:id="_DFMEvwg">All 60 patients were included in the intention-to-treat analysis.</s></p><p xml:id="_bMAUer6"><s xml:id="_YYGrdrM">In total, 26 patients (43%) were female and 35 (58%) were White (Table <ref type="table" target="#tab_1">1</ref>).</s><s xml:id="_DfumSsX">Baseline characteristics were slightly different between the arms based on absolute standardized differences but were well-balanced on key metrics including age, sex, baseline HbA1c values, and baseline adherence.</s></p><p xml:id="_Pup2kYp"><s xml:id="_dgjwe8V">Intervention group patients had less formal education (e.g., 24.1% vs. 16.1% having no more than a high school education) and took more oral diabetes medications (31% vs. 19% taking ≥2 medications) versus control patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fPcfHaE">Description of the reinforcement learning algorithm learning process</head><p xml:id="_c5eS4vh"><s xml:id="_3GUcten">In total, 5143 text messages were sent to patients in the intervention arm (n = 29) during the 6-month study period.</s><s xml:id="_BnmnxC9">Intervention patients received daily messages; an average of 27.7 (SD: 5.9) unique messages were sent to each patient (Table <ref type="table" target="#tab_2">2</ref>).</s><s xml:id="_F3XgC8t">In aggregate, 514 (10.0%), 2473 (48.1%), and 2058 (40.0%) of text messages contained ≥3, ≥4, and ≥5 behavioral factors respectively.</s></p><p xml:id="_9VVrzGy"><s xml:id="_sEvd6Ca">The reinforcement learning algorithm also adapted its selection of behavioral factors in the text messages; the proportions of intervention arm patients who received the five factors over the trial are shown descriptively in Supplemental Fig. <ref type="figure">1</ref> panels.</s><s xml:id="_5pdBNSu">For example, positive framing as a factor (Supplemental Fig. <ref type="figure">1a</ref>) was initially not frequently selected by the algorithm during the first two months of the trial but became more prevalent later.</s><s xml:id="_vRN93uR">By contrast, negative framing was more commonly selected at first but decreased over time (Supplemental Fig. <ref type="figure">1b</ref>).</s><s xml:id="_bgNk4a6">Other plots for receipt of history, social reinforcement, content, and reflection are shown in Supplemental Fig. <ref type="figure">1c-f</ref>, respectively.</s><s xml:id="_4WbbAY8">More patients were selected to receive social reinforcement, content, and reflection as factors as the trial progressed, while the proportion of patients receiving history (observed feedback) remained relatively equal over time.</s></p><p xml:id="_8KeHZV8"><s xml:id="_j2XXSDr">Figure <ref type="figure">2</ref> shows the change in adjusted R 2 of the reinforcement learning algorithm over the trial.</s><s xml:id="_rEFKvgK">This statistic, which describes the extent to which adherence is explained by algorithm predictions for behavior following a message sent to participants, increased over time, indicating that the algorithm learned to send more effective messages to patients.</s></p><p xml:id="_sVVwvwY"><s xml:id="_RQSxRZs">The most influential features and interactions from the reinforcement learning algorithm are shown in Fig. <ref type="figure" target="#fig_0">3</ref>. Fixed characteristics that carried the most weight within the model were baseline HbA1c, self-reported level of patient activation, number of medications included in electronic pill bottles, concomitant insulin use, and employment status based on their interactions.</s><s xml:id="_tuAzur9">The behavioral factors with the largest weight included positive framing, observed feedback, and social reinforcement.</s></p><p xml:id="_XyQNtxe"><s xml:id="_56mMvZk">Effect of the reinforcement learning intervention on the primary outcome Over the 6-month follow-up, average adherence to medication was 74.3% (SD: 30.8%) in the reinforcement learning intervention arm compared with 67.7% (SD: 29.4%) in the control arm (Fig. <ref type="figure">4</ref>).</s><s xml:id="_xcHMK3h">After adjusting for the block randomized design and baseline characteristics, average adherence among intervention patients was 13.6% (95%CI: 1.7%, 27.1%, p = 0.047) higher than control (shown in Fig. <ref type="figure">4</ref>).</s><s xml:id="_cQPYhTz">Sensitivity analyses, including omitting the first two weeks of pill bottle data and censoring patients in both arms after 30 days of pill bottle non-use (3 patient and 1 patient in intervention and control arms, respectively) did not change the results (Supplemental Table <ref type="table" target="#tab_1">1</ref>).</s></p><p xml:id="_69JCCSu"><s xml:id="_qxBxWhQ">Hypothesis-generating demographic and clinical subgroup analyses that explored interactions between patient characteristics and the intervention's effectiveness on adherence are also shown in Fig. <ref type="figure">4</ref>. The strongest interaction between the overall effectiveness of reinforcement learning and adherence was by baseline HbA1c level.</s><s xml:id="_WbUWxrW">Specifically, in patients with HbA1c 7.5-&lt; 9.0%, the intervention improved adherence by 33.6% (95%CI: 15.9%, 51.4%) versus control contrasted with those with baseline HbA1c ≥ 9% (interaction p value: 0.001) in which there was no significant difference compared with control.</s><s xml:id="_W6dSzs4">In patients who were non-adherent at baseline (i.e., self-reported missing &gt;1 medication dose in the 30 days before enrollment), the intervention improved adherence by 33.0% (95%CI: 13.1%, 52.8%) versus control, but this interaction was not significant (interaction p value: 0.214).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KY2FCwy">Exploratory analyses of responsiveness to behavioral factors</head><p xml:id="_68hd4AH"><s xml:id="_M9v2NZK">In hypothesis-generating analyses, we whether responsiveness to the tested behavioral factors (determined by optimal adherence) differed by patient baseline characteristics.</s><s xml:id="_7MpCPEB">As shown in Fig. <ref type="figure">5</ref>, patients who were aged &lt;65 years (compared with ≥65), were of White race/ethnicity (compared with non-White), had HbA1c &lt; 9% (compared with ≥9%), were of other marital status (compared with married/partnered), and were taking multiple medications (compared with 1) responded better than their counterparts to most or almost all behavioral factors.</s><s xml:id="_G6JW7hn">In contrast, women were more responsive to messages reporting their medication-taking history than men but were less responsive to other factors.</s><s xml:id="_Qb9jmjr">Finally, patients who were more non-adherent at baseline (self-reported missing &gt;1 dose, compared to those who reported missing ≤1 doses in the last 30 days) were more responsive to positivelyframed messages and less responsive to messages reporting their medicationtaking history, but had similar responsiveness to all other factors.</s></p><p xml:id="_jVPFnSp"><s xml:id="_57b7k9n">Adherence differed based on whether that behavioral factor had been sent the prior day (Fig. <ref type="figure">6</ref>).</s><s xml:id="_tgC6jjw">For instance, adherence was highest when negatively-framed messages and messages containing observed medication feedback were sent two days in a row (i.e., red columns).</s><s xml:id="_pnNutnK">By contrast, no difference in adherence was observed when text messages including and not including the behavioral factor were alternated.</s></p><p xml:id="_ZzgJEXb"><s xml:id="_SYk4Y6z">Using k-means clustering analysis of average adherence given the behavioral factors, we identified three unique patient clusters (Fig. <ref type="figure" target="#fig_2">7</ref>).</s><s xml:id="_MJGvZvu">These clusters included: (1) Group 1 (Orange, n = 9) responding best to observed feedback, (2) Group 2 (Yellow, n = 4) responding best to social reinforcement and observed feedback, and (3) Group 3 (Blue, n = 16) responding equally to all message types.</s><s xml:id="_v72mKE7">Individuals who were married/partnered were more likely to be in Group 1 compared with the other two groups, but most associations were non-significant owing at least in part to small sample size (Table <ref type="table" target="#tab_6">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_x4bzHcp">Discussion</head><p xml:id="_VEw6737"><s xml:id="_MXqXdmE">In this randomized-controlled trial of a reinforcement learning intervention that personalized text messaging content for patients with diabetes (and HbA1c ≥ 7.5%, above most guideline targets), we found that the intervention improved adherence to medication over a 6-month follow-up.</s><s xml:id="_aCECByr">The intervention was particularly effective among patients with HbA1c between 7.5 and 9.0%.</s><s xml:id="_FseT2mt">Adherence changes of this magnitude have been associated with differences in patient outcomes and health care spending <ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37</ref> .</s></p><p xml:id="_vy3yucH"><s xml:id="_bSUbEk9">Numerous trials have demonstrated that text messages support adherence to medication <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref> . However,</s><s xml:id="_JyzR8ZD">the effectiveness of many prior approaches has been limited, in part because they have not personalized the content and presentation of the messages patients receive 38 .</s><s xml:id="_yJfWxV4">To our knowledge, no study has personalized text messages for adherence in realtime on a daily basis through latent measurement of adherence and response, especially using reinforcement learning.</s><s xml:id="_B7e2Nmt">Some prior work has personalized text messages for adherence based on simple user characteristics, preferences or self-reported adherence, at pre-specified intervals, or through relatively static "if-then" rules, but have not adapted based on observing what patients respond to <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref> .</s><s xml:id="_NK8Cdrv">Reinforcement learning has indicated early promise for other health behaviors.</s><s xml:id="_HvpNDDR">For example, a 3-arm trial of 27 patients tested the impact on physical activity of different text messaging approaches for individuals with type 2 diabetes, finding that text messaging using reinforcement learning resulted in significant more physical activity and lower HbA1c values than non-personalized weekly texting strategies <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b26">27</ref> .</s><s xml:id="_nTXenbm">Reinforcement learning interventions for titrating antiepilepsy medications and selecting sepsis protocols have also demonstrated effectiveness <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b40">41</ref> .</s></p><p xml:id="_fFpmxUF"><s xml:id="_qzcuA6W">The reinforcement learning intervention appears to have learned from patient observations and changed the messages that it selected over time.</s><s xml:id="_zjQeCuq">This was particularly evident in its approach to message framing.</s><s xml:id="_4q9Vd7b">The algorithm initially favored negatively framed messages (e.g., highlighting the negative disease consequences of non-adherence to medication) but over time, there was a noticeable shift such that more patients</s></p><p xml:id="_3taFQ6C"><s xml:id="_8ewn6vZ">262 patients approved by providers (89.4%) 74 were unable to be reached 56 were reached and declined further screening 10 did not have a smartphone 12 reported cognitive issues affecting medication management 13 did not want to use study pill bottles 8 did not want adherence intervention 18 did not meet other criteria (stopped diabetes medication, lack of working English knowledge, enrolled in another diabetes trial) 60 randomized (84.5%) 71 consented (27.1%) 293 potentially eligible patients identified from the electronic health record system sent to providers for approval 11 withdrew before randomization Reinforcement learning (N=29) Control (N=31) 29 included in intention-to-treat analysis 31 included in intention-to-treat analysis 1 withdrew 2 withdrew 1 deceased Fig. 1 | CONSORT diagram.</s><s xml:id="_mWX7tEM">This diagram shows a visual representation of the flow of patients through the trial.</s><s xml:id="_7wJ44Ee"><ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref></s></p><p xml:id="_bGpwhsf"><s xml:id="_ZBwDbhe">received either a neutral tone or positively framed message (e.g., highlighting positive consequences of adherence).</s><s xml:id="_spTh2CT">This change was also seen quantitatively with the increasing proportion of variance in daily adherence explained by the behavioral factors in the text messages (i.e., the adjusted R 2 ).</s><s xml:id="_8VrRa4G">By the end of the trial, the adjusted R 2 was consistently over 0.40, meaning that much of the difference in adherence on a given day could be explained by the five algorithm factors.</s><s xml:id="_sjRwjYB">Additional features, for example, the interaction between positive framing and observed feedback as well as higher HbA1c and patient activation provided the greatest weight to the model prediction, suggesting that the algorithm incorporated learned information.</s><s xml:id="_JwTT5dX">Together, these findings suggest that the reinforcement learning algorithm not only changed its strategy over time but also improved its performance in predicting what types of messages would improve individuals' adherence.</s><s xml:id="_8vchAM3">The intervention was also particularly effective in patients with HbA1c between 7.5 and 9.0%.</s><s xml:id="_6znVyyk">The reason for this can be explained in two ways; first, patients further from guideline targets may need treatment intensification in addition to better adherence to their existing medications <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_8anpDMc">Second, a prior trial also suggested that individuals have varying preferences for how to escalate diabetes care at different levels of HbA1c values; those with HbA1c between 7.5 and 9.0% were more interested in adherence support than other interventions <ref type="bibr" target="#b15">16</ref> .</s><s xml:id="_Va7jyku">While less pronounced and not statistically significant, patients reporting worse adherence at baseline also tended to respond more to the intervention.</s><s xml:id="_qNhP9cm">This may also have been due to the fact that individuals who report missing multiple doses in the last 30 days most likely have substantial non-adherence <ref type="bibr" target="#b41">42</ref> and are an ideal target population for an adherence intervention.</s></p><p xml:id="_y9wbeRn"><s xml:id="_ePgbUEg">Supporting the potential benefits of personalization and for generating future hypotheses, we explored characteristics of patients who responded differently to different message types.</s><s xml:id="_HMCpkT8">The most notable was that women</s></p><p xml:id="_TREvByy"><s xml:id="_UNGHy26">Adjusted R 2 -0.4 -0.2 0 0.2 0.4 0.6 0.8 1 31 37 43 49 55 61 67 73 79 85 91 97 103 109 115 121 127 133 139 145 151 157 163 169 175 181 187 193 199 205 211 217 223 229 235 241 247 253 259 265 Day of the trial Fig. 2 | Change in reinforcement learning algorithm adjusted R 2 over the course of the trial.</s><s xml:id="_hg4qECG">The adjusted R 2 from trial calendar day 31 to 279 (March 13, 2021-December 19, 2021) is plotted from each day's model.</s><s xml:id="_QN6ukMa">We calculated adjusted R 2 from the proportion of variance in daily adherence that is explained by the five intervention factors in the reinforcement learning model.</s><s xml:id="_F4hvSGy">We selected those windows as they each had a minimum of 5 patient observations that day.</s><s xml:id="_WZyKSNT">0 0.0005 0.001 0.0015 0.002 Female sex*Employment status HbA1c≥10%*SGLT2 inhibitor use HbA1c≥10%*Age 65-74 History*White race/ethnicity HbA1c≥10%*Insulin use HbA1c≥10%*Marital status No. of physicians*HbA1c≥10% History*HbA1c≥10% HbA1c 9-9.9%*No. of medications HbA1c 9-9.9%*Sulfonylurea use HbA1c 9-9.9%*Age 45-54 HbA1c 9-9.9%*White race/ethnicity HbA1c 9-9.9%*Patient_activation</s><s xml:id="_FUCQ35Y">History*employment status History*social History*insulin use HbA1c ≥10%*No.</s><s xml:id="_nxaKnYQ">twice daily pillbottles History HbA1c ≥10%*Patient activation Positive framing*History Model weights <ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref></s></p><p xml:id="_YJ4benq"><s xml:id="_vm245g2">responded better to receiving observed feedback about their medicationtaking than men but responded less well to positive framing, social messaging, informational messaging rather than reminders, and messages that were intended to provoke reflection.</s><s xml:id="_G5EW5ES">One explanation could be that some women are already aware of how their own health can benefit loved ones and may prefer more straightforward reminders and feedback about their medication-taking performance <ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b42">43</ref> , although future work should explore further within larger sample sizes.</s></p><p xml:id="_GVHYxzb"><s xml:id="_Ps439p3">In our exploratory analyses, there were clusters of patients who responded to different types of messages.</s><s xml:id="_hkYEmzJ">In specific, one group responded best to observed feedback, and a second group responded best to social reinforcement and observed feedback, while a third responded</s></p><p xml:id="_TuPRYZ5"><s xml:id="_NRC43Hs">Primary analysis: Adherence to medication Key subgroup analyses Patient age &lt;65 years (n = 37) .</s><s xml:id="_KWZcFD4">Patient sex Female (n = 26) Male (n = 34) Patient race/ethnicity White (n = 34) Non-White (n = 26) Marital status Marrier/partner (n = 30) Other (n = 30) Baseline HbA1c &lt;9% (n = 34) Diabetes medication use &lt;4 years (n = 23) 1 (n = 45) Baseline adherence .. &gt;1 dose missed (n = 26)</s></p><p xml:id="_5g9zN9R"><s xml:id="_qNRFMEf">13.6% (1.7%, 27.1%) 12.9% (-9.6%, 35.3%) 7.0% (-7.3%, 21.2%) -4.6% (-30.8%,</s><s xml:id="_yjtzeeg">21.5%) 4.5% (-8.1%, 17.0%) 11.1% (-6.3%, 28.5%) 4.3% (-15.5%,</s><s xml:id="_cneV5kM">24.0%) 16.6% (0.4%, 32.9%) 33.6% (15.9%, 51.4%) 36.6% (25.1%, 48.2%) -4.6% (-28.4%,</s><s xml:id="_J6sMtJf">19.2%) 35.1% (-1.8%, 71.9%) 1.9% (-10.2%,</s><s xml:id="_cnn8kbW">14.1%) 17.5% (1.4%, 33.7%) 13.1% (-25.9%,</s><s xml:id="_MMzm97Z">52.1%) 10.1 (-4.6%, 24.9%) 33.0% (13.1%, 52.8%) 0.507 0.353 0.214 0.001 0.876 0.812 0.356 -30 -20 -10 0 10 20 30 40 50 60 70 ≥65 years (n = 23) .≥..9% (n = 26) .≥ 2 (n = 15)</s></p><p xml:id="_yVSnJp5"><s xml:id="_nDsH8Rv">≤.1 doses missed (n = 34) .≥..4 years (n = 37)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hgCsxCC">Number of medications</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uc5QkeA">Adjusted absolute difference, 95%CI Interaction p-values Absolute difference</head><p xml:id="_s6PhZ45"><s xml:id="_H8qbQGN">Favors reinforcement learning Favors control 0.702 Fig. <ref type="figure">4</ref> | Trial primary outcome and subgroup analyses.</s><s xml:id="_ZEzxKv9">We used generalized estimating equations with an identity link and normally-distributed errors to evaluate the effect of the intervention on adherence to medication measured by pill bottles compared with control.</s><s xml:id="_dAhcRYy">The points on the figure are the point estimates and the error bars are the 95% confidence intervals from the relevant sample sizes.</s><s xml:id="_gKK8N8e">These models were adjusted for baseline characteristics and the block randomized design.</s><s xml:id="_ZjPwWwb">The primary outcome is shown at the top.</s><s xml:id="_ukYwHyC">The results of exploratory subgroup analyses by key demographic and clinical characteristics also shown; these were performed by repeating the same models within each subgroup, using interaction p-values to assess between subgroups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_n5w8QQy">Fig. 5 | Relationship between patient characteristics and responsiveness to individual behavioral factors.</head><p xml:id="_ugeRzgH"><s xml:id="_ssA37qe">This figure shows the results of these exploratory analyses with the outcome being optimal adherence (adherence=1) for the day after the factor was selected and sent within the text message.</s><s xml:id="_7GsEFaF">We used generalized estimating equations for each behavioral factor with a log link and binarydistributed errors, adjusted for patient baseline characteristics but unadjusted for patient-level clustering.</s><s xml:id="_yxxyG9f">Light red indicates a negative association (Relative risk 0.50-0.99);</s><s xml:id="_bw24Qkp">Light blue indicates a positive association (Relative risk</s></p><p xml:id="_VTnAe9T"><s xml:id="_NqxkHdV">1.01-1.50);</s><s xml:id="_sWeuVX5">and Dark blue indicates a strong positive association (Relative risk ≥1.50).</s><s xml:id="_Ryzznaj">Abbreviations: CI Confidence interval, HbA1c glycated hemoglobin A1c.</s><s xml:id="_GH2pEsg">Positive Framing Negative Framing History (Observed feedback) Social Content Reflective Baseline characteristic Relative Risk (95%CI) Patient age &lt;65 years vs. ≥65 years 1.29 (1.23-1.36)</s><s xml:id="_AgJZQsP">0.97 (0.76-1.23) 1.03 (0.97-1.09) 1.27 (1.21-1.33)</s><s xml:id="_gxnpwYH">1.24 (1.18-1.29)</s><s xml:id="_Bchz4Fz">1.25 (1.19-1.30)</s><s xml:id="_Afayx55">Patient sex Female vs. Male 0.90 (0.87-0.94) 0.97 (0.80-1.19) 1.04 (1.00-1.09)</s><s xml:id="_7Phecae">0.90 (0.86-0.93) 0.90 (0.87-0.94) 0.90 (0.86-0.94)</s><s xml:id="_ZbBfXXP">Patient race/ethnicity White vs. Non-White 1.22 (1.16-1.29)</s><s xml:id="_vGqQfk3">0.98 (0.81-1.18) 1.10 (1.05-1.15)</s><s xml:id="_27u9hvQ">1.18 (1.12-1.24)</s><s xml:id="_6AxaPqQ">1.14 (1.09-1.19)</s><s xml:id="_KepaREb">1.15 (1.10-1.21)</s><s xml:id="_4EETN3p">Marital status Married/partnered vs. other 0.88 (0.85-0.92) 1.05 (0.89-1.23) 1.02 (0.98-1.06) 0.88 (0.84-0.92) 0.88 (0.84-0.92) 0.89 (0.85-0.93)</s><s xml:id="_6G4KDmA">Baseline HbA1c &lt;9% vs. ≥9% 2.05 (1.16-1.29)</s><s xml:id="_eTXRKBM">1.60 (1.32-1.94)</s><s xml:id="_WwtqRwD">1.14 (1.08-1.20)</s><s xml:id="_7SRZMhu">2.06 (1.93-2.20)</s><s xml:id="_cxmUY7e">2.06 (1.93-2.20)</s><s xml:id="_6b53GqY">2.07 (1.94-2.21)</s><s xml:id="_rn3zM9n">Diabetes medication use ≥4 years vs. &lt;4 years 1.04 (0.99-1.09) 0.89 (0.70-1.14) 0.95 (0.90-1.01) 1.03 (0.98-1.09) 1.02 (0.97-1.08) 1.01 (0.96-1.06)</s><s xml:id="_btUZXJu">Number of medications ≥2 vs. 1 1.05 (0.98-1.12) 1.09 (0.97-1.37) 1.02 (0.97-1.08) 1.08 (1.01-1.15)</s><s xml:id="_NzG6Jsu">1.10 (1.04-1.17)</s><s xml:id="_DP786sF">1.09 (1.02-1.16)</s><s xml:id="_K9WjEjF">Baseline adherence &gt;1 vs. ≤1 doses missed 1.04 (1.00-1.08)</s><s xml:id="_rNqMMtk">0.94 (0.79-1.12) 0.95 (0.91-0.98) 1.02 (0.98-1.06) 1.02 (0.98-1.06) 1.02 (0.98-1.05) <ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref></s></p><p xml:id="_sqXhkmZ"><s xml:id="_cPmeYVs">equally to all types of messages.</s><s xml:id="_UrNQXjE">We also found higher adherence when negatively-framed messages and messages that contained observed feedback were provided two days in a row, perhaps reflecting the need to reinforce these types of messages, but not others.</s><s xml:id="_qqvpDzB">The fact that the algorithm de-prioritized negative framing on average over time but that it was effective in combination with observed feedback is also worthy of consideration.</s><s xml:id="_hRMDjRd">This could in part be explained by underlying heterogeneity of the patient population in their responsiveness, and in how the information was sequenced, emphasizing the potential impact of personalization but should be explored further.</s></p><p xml:id="_3qeS2wm"><s xml:id="_BxjcQz2">Future work could extend these findings in several ways.</s><s xml:id="_jSDE62D">First, researchers should test the added impact of using reinforcement learning with non-personalized text messages.</s><s xml:id="_t24wW2n">Second, the impact of a reinforcement learning intervention should be tested on long-term clinical outcomes and in a larger and more diverse sample to confirm some of the exploratory analyses about responsiveness to different behavioral factors.</s><s xml:id="_jY7neAb">Finally, this Fig. <ref type="figure">6</ref> | Average adherence across behavioral factors stratified by the sequence of text messages the prior day and the same day the message was sent.</s><s xml:id="_D8fTQRT">This figure shows the average daily adherence measured by pill bottle over the course of the trial among the 29 intervention arm participants.</s><s xml:id="_fgAQPgq">These results are stratified by the text message sent in the prior day and/or the same day contained that intervention factor (e.g., positive framing).</s><s xml:id="_t8Ubagt">For example, the dark blue bar for "positive framing" indicates the level of adherence if the prior's day text message contained positive framing but that day's text message did not.</s></p><p xml:id="_yZkwqE6"><s xml:id="_xpF4fym">Text message that day and the day before did not contain the factor (Today=0; Previous Day=0) Text message that day did not contain the factor but the day before did (Today=0; Previous Day=1) Text message that day contained the factor but the day before did not (Today=1; Previous Day=0) Text message that day and the day before contained the factor (Today=1; Previous Day=1) Each color represents one of the three different patient groups identified from the exploratory k-means clustering analysis for the average pill bottle adherence measured over 6 months (primary outcome).</s><s xml:id="_dnSBRMF">These groups include: (1) Group 1 (Orange, n = 9) was the most adherent in response to observed feedback ("history"), (2) Group 2 (Yellow, n = 4) was the most adherent in response to social reinforcement or observed feedback, and (3) Group 3 (Blue, n = 16) was equally adherent in response to all types of messages.</s><s xml:id="_Yabu7C9">The error bars show the standard error for the cluster based on the underlying sample size (i.e., a threshold of ≥25 observations was applied).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bDhgjPc">Average adherence</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XFSKW6Z">Positive</head><p xml:id="_bdhDe3x"><s xml:id="_dWSbT6k"><ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref></s></p><p xml:id="_RxeBWnj"><s xml:id="_ByzD4qz">work could be applied in other ways, for example to other disease states or related guideline-recommended daily activities such as physical activity or diet.</s><s xml:id="_tERkykQ">Several limitations should be acknowledged.</s><s xml:id="_BrSqebN">First, electronic pill bottles could have influenced adherence, especially during the initial period of observation; however, they have been shown to correlate strongly with actual pill consumption <ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b44">45</ref> , and we minimized this observer bias by using pill bottles in both arms.</s><s xml:id="_bTHRCMg">While we powered the study to detect a 10% difference in adherence, the standard deviations were wider than anticipated, likely owing to the small sample size and overall heterogeneity in medication-taking than previously observed <ref type="bibr" target="#b45">46</ref> .</s><s xml:id="_Ct5P89t">The findings may also not generalize to patients with pre-diabetes or gestational diabetes or those without reliable access to a smartphone.</s><s xml:id="_TEabnFZ">The subgroup and responsiveness analyses were also limited by small sample sizes and should be considered exploratory.</s><s xml:id="_ffparnF">It is also currently technologically less feasible to passively measure adherence to injectable agents in a scalable manner, and oral diabetes medications are the cornerstone of first and second-line type 2 diabetes treatments.</s><s xml:id="_4DatyNv">Finally, we also chose not to have a "generic" text messaging arm, in part to test the highest possible efficacy of the intervention so we cannot assess the incremental benefit of personalization versus generic messaging with this design.</s></p><p xml:id="_AgRjhFn"><s xml:id="_qQXmVdd">In conclusion, the reinforcement learning intervention led to improvements in adherence to oral diabetes medication and was particularly effective in patients with HbA1c between 7.5 and 9.0%.</s><s xml:id="_gnPMwkw">This trial provides insight into how reinforcement learning could be adapted at scale to improve other self-management interventions and provides promising evidence for how it could be improved and tested in a wider population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3JekEam">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QRGTDYc">Study design</head><p xml:id="_DsdrMCT"><s xml:id="_egfAKt6">Trial design details have been previously published <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_qzDHpyc">The protocol was designed, written, and executed by the investigators (Fig. <ref type="figure">1</ref>).</s><s xml:id="_6uWaRs9">Study enrollment began in February 2021 and completed in July 2021.</s><s xml:id="_FmVd24g">Follow-up of all patients ended in January 2022; the final study database was available in March 2022.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NhYUfET">Study population and randomization</head><p xml:id="_UtjW4Ds"><s xml:id="_mdqYqHS">The trial was conducted at Brigham and Women's Hospital (BWH), a large academic medical center in Massachusetts, USA.</s><s xml:id="_wYUyRXb">Potentially-eligible patients were individuals 18-84 years of age diagnosed with type 2 diabetes and prescribed 1-3 daily oral diabetes medications, with their most recent glycated hemoglobin A1c (HbA1c) level ≥7.5% (i.e., above guideline targets) <ref type="bibr" target="#b46">47</ref> .</s><s xml:id="_HYPFM3U">These criteria were assessed using BWH electronic health record (EHR) data.</s><s xml:id="_thAuQpm">To be included, patients also had to have a smartphone with ability to receive text messages, have working knowledge of English, not be enrolled in another diabetes trial at BWH, not use a pillbox or switch to using electronic pill bottles for their diabetes medications for the study, and be independently responsible for taking medications.</s><s xml:id="_wRB4gVC">Smartphone connectivity was essential to measure daily adherence, but they have been widely adopted, even among patients from socioeconomically disadvantaged backgrounds <ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b48">49</ref> .</s><s xml:id="_7hHxuwb">Patients using insulin or other diabetes injectables in addition to their oral medication were allowed to be included to enhance generalizability.</s></p><p xml:id="_eSQAXyf"><s xml:id="_dJtYPu4">As previously described <ref type="bibr" target="#b21">22</ref> , potentially eligible patients with a recent or upcoming diabetes clinic visit were identified from the EHR on a biweekly basis.</s><s xml:id="_JGYxhYM">Once identified, the patients' endocrinologists were contacted for permission to include their patient(s) in the study.</s><s xml:id="_t2jufFR">Patients approved for enrollment were sent a letter on their endocrinologist's behalf inviting them to participate and were then contacted by telephone.</s><s xml:id="_9y2BEHN">Patients who agreed provided their written informed consent captured through REDCap electronic data capture tools <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51</ref> , completed a baseline survey containing measures including demographics, self-reported adherence <ref type="bibr" target="#b41">42</ref> , health activation <ref type="bibr" target="#b51">52</ref> , and automaticity <ref type="bibr" target="#b52">53</ref> of medication-taking, and were mailed a separate Pillsy ® electronic pill bottle for each of their eligible diabetes medications (i.e., each patient received between 1-3 pill bottles).</s><s xml:id="_JaxUNDk">Electronic pill bottles have been widely used in prior research and have shown high concordance with other measurement methods <ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b53">54</ref> .</s><s xml:id="_We3uYJR">The data from the pill bottles were transmitted through the patients' smartphones via an app that otherwise had no features enabled for the app or pill bottles (i.e., any latent adherence reminders through the pill bottle were turned off).</s><s xml:id="_48srN7v">A figure of the infrastructure has been previously published <ref type="bibr" target="#b21">22</ref> .</s></p><p xml:id="_skFU2Eb"><s xml:id="_buVt5At">After receiving the pill bottles, patients were randomized in a 1:1 ratio to intervention or control using block randomization based on baseline level of self-reported adherence (i.e., ≤1 dose or &gt;1 doses missed in the last 30 days <ref type="bibr" target="#b41">42</ref> ) and (2) baseline HbA1c of &lt;9.0% or ≥9.0% 2 .</s><s xml:id="_Av3WFnn">Patients were asked to use these devices instead of regular pill bottles or pillboxes for their eligible oral diabetes medications.</s><s xml:id="_MFM5AZz">After randomization, patients were followed for 6 months for outcomes.</s><s xml:id="_Rpf5aD8">At the end of follow-up, patients were contacted to complete a follow-up survey and ensure complete synchronization of their pill bottles.</s><s xml:id="_2pmWNBn">Both arms received a $50 gift card for participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PUQ8Gx4">Intervention</head><p xml:id="_cUVfS3h"><s xml:id="_YmbefmA">The intervention was a reinforcement learning text messaging program that personalized daily text messages based on the electronic pill bottle data.</s><s xml:id="_eP8tuAN">Messages were selected by the Microsoft Personalizer ® algorithm <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b23">24</ref> , a reinforcement learning system which aimed to achieve the highest possible sum of "rewards" over time, and which adapted over time by monitoring the success of each message to nudge patients to adhere to their medications.</s></p><p xml:id="_KqwNA9Z"><s xml:id="_FJZj2C3">The messages were based on behavioral science principles of how content influences patient behavior <ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref> .</s><s xml:id="_DqpUtZ3">Based on qualitative interviews <ref type="bibr" target="#b57">58</ref> , Self-reported baseline adherence: &gt;1 dose missed vs. ≤1 dose missed 0.64 (0.12-3.53) 1.29 (0.14-11.54)</s></p><p xml:id="_JYMAeYJ"><s xml:id="_TkH2T9T">Among 29 intervention arm patients, we used exploratory multinomial logistic regression comparing baseline patient characteristics of those in Group 1 (responding best to observed feedback [history], n = 9, Orange in Fig. <ref type="figure">6</ref>) and Group 2 (responding best to social reinforcement or observed feedback, n = 4, Yellow in Fig. <ref type="figure">6</ref>) using Group 3 as the referent group (responding equally to each factor, n = 16, Blue in Fig. <ref type="figure">6</ref>).</s><s xml:id="_rNKWthq">a p &lt; 0.05.</s><s xml:id="_UGdQkah">CI Confidence Interval.</s></p><p xml:id="_p8SEJTX"><s xml:id="_Pb3pNwk">we selected 5 behavioral factors for the messages: (1) framing (classified as neutral, positive [invoking positive outcomes of medication use], or negative [invoking consequences of medication non-use]), (2) observed feedback ("History", i.e., including the number of days in the prior week the patient was adherent), (3) social reinforcement ("Social"), (4) whether content was reminder or informational ("Content"), and (5) whether the text included a reflective question ("Reflective") <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b58">[59]</ref><ref type="bibr" target="#b59">[60]</ref><ref type="bibr" target="#b60">[61]</ref> .</s><s xml:id="_2vpFBde">We designed ≥2 text messages for each unique set of factors (i.e., 47 unique sets across 128 text messages); examples of the factors sets contributing to the reinforcement learning model have been published <ref type="bibr" target="#b21">22</ref> .</s></p><p xml:id="_vSZChPA"><s xml:id="_jAq9N2z">Every day, adherence from the prior day was measured by the electronic pill bottles, with values ranging from 0 to 1 based on the fraction of daily doses taken across their diabetes medications, averaging if they are taking multiple medications <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_4V3AGca">These served as the "reward" events used to provide feedback to Microsoft Personalizer ® .</s><s xml:id="_QEAbUzZ">The algorithm learned to predict which factors should have been included in the message on a given day to maximize the rewards that the algorithm received (i.e., adherence).</s></p><p xml:id="_y2R3ACj"><s xml:id="_829UEVj">The algorithm used several attributes to predict which factors to select.</s><s xml:id="_DPfpdmB">These included patient baseline characteristics (e.g., age, sex, race/ethnicity, number of medications, concomitant insulin use, self-reported patient activation, education level, employment status, marital status, and therapeutic class), the number of days since each factor had last been sent, and whether the medication had already been taken before the algorithm was run for that day.</s><s xml:id="_QmFnNZw">The algorithm was trained to predict whether or not to include each aspect separately using a "contextual bandit" framework <ref type="bibr" target="#b61">[62]</ref><ref type="bibr" target="#b62">[63]</ref><ref type="bibr" target="#b63">[64]</ref> .</s><s xml:id="_6qS2R2D">The specific message to be sent was randomly selected from messages matching the required aspects.</s></p><p xml:id="_xEZserU"><s xml:id="_tDRsw2a">The text messages were sent on a daily basis to patients using a thirdparty SMS platform, including an introductory text and simple reminder text to synchronize their pill bottles if they had not been connected for ≥7 days.</s></p><p xml:id="_CgcVw6K"><s xml:id="_knkcMjm">Patients in the control arm received the same introductory and simple reminder text to synchronize their pill bottles if they had not been connected for ≥7 days but otherwise received no intervention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AsWUhuM">Study outcomes</head><p xml:id="_pdUg8Sd"><s xml:id="_WVja9Yc">The trial's primary outcome was medication adherence assessed in the 6 months after randomization using the average daily adherence for each patient (which already averaged across multiple medications) <ref type="bibr" target="#b21">22</ref> .</s><s xml:id="_YF55QzQ">While other secondary outcomes were measured, we focus on the primary outcome and related analyses in this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_n7937P8">Statistical analysis</head><p xml:id="_jHyC3Re"><s xml:id="_GmEKFFj">The overall trial was powered to detect a 10% difference in average adherence over the 6-month follow-up, assuming a SD = 12.5%.</s><s xml:id="_zp5USYy">We reported key sociodemographic and clinical pre-randomization variables separately for intervention and control using absolute standardized differences (imbalance as a difference &gt;0.1) <ref type="bibr" target="#b64">65</ref> .</s><s xml:id="_vdbtJYa">Intention-to-treat principles were used for all randomized patients, with a two-sided hypothesis tested at α = 0.05.</s><s xml:id="_N6pP7Eg">We used SAS 9.4 (Cary, NC) for analyses.</s></p><p xml:id="_4hQZWxp"><s xml:id="_nxkTncb">The process and performance of the reinforcement learning algorithm were descriptively examined.</s><s xml:id="_tNMZ9Kg">The average proportion of patients who received each behavioral factor was estimated and plotted over time for each individual patient.</s><s xml:id="_D6FKzuQ">To explore the extent to which adherence was explained by algorithm predictions each day, the adjusted R 2 based on the algorithm predictions was estimated for each day over the trial.</s><s xml:id="_pMCYNhx">Specifically, we calculated the proportion of variance in daily adherence that was explained by just the five intervention factors.</s><s xml:id="_cG8n73H">We also explored the most influential features selected by the model when predicting which messages to send for the entire follow-up period; higher scores indicates more influence to the model.</s></p><p xml:id="_duwYJbq"><s xml:id="_f4QtFZQ">For the primary outcome, we evaluated the effect of the reinforcement learning intervention on adherence using generalized estimating equations with an identity link function and normally distributed errors.</s><s xml:id="_6uw3Psy">These models were adjusted for the block-randomized design, and given imbalances in some important covariates, also controlled for differences in measured baseline characteristics.</s><s xml:id="_MBEger2">Some of these imbalances included: more patients in the intervention arm with no more than a high school education (24.1% vs. 16.1%),</s><s xml:id="_bWePgmS">fewer intervention patients who were married/or partnered (44.8% vs. 54.8%),</s><s xml:id="_BdWjkpE">and more intervention patients taking multiple diabetes medications (31.0% vs. 19.4%).</s><s xml:id="_Zw8n5Dx">Each of these characteristics have been shown previously to influence adherence <ref type="bibr" target="#b65">66,</ref><ref type="bibr" target="#b66">67</ref> .</s><s xml:id="_AhEcJx3">Exploratory subgroup analyses were performed according to key demographic/clinical subgroups including age, sex, race/ethnicity, marital status, baseline HbA1c, number of years using oral diabetes medications, baseline self-reported adherence, and number of pill bottle medications.</s><s xml:id="_YPPr4A9">There was no missing data for the primary outcome.</s><s xml:id="_A9e2J8Y">Several other sensitivity analyses were also conducted, including omitting the first 14 days for observer effects <ref type="bibr" target="#b43">44</ref> and censoring patients in both arms when the pill bottles were not connected for ≥30 days.</s></p><p xml:id="_MQ5JC5n"><s xml:id="_WCzQfXT">Additional exploratory and descriptive analyses of adherence in response to the intervention factors were also conducted for future hypothesis generation.</s><s xml:id="_yGtHE7E">First, the associations between key baseline characteristics and optimal adherence (i.e., adherence value = 1 for the subsequent day) by behavioral factor for intervention patients were explored.</s><s xml:id="_YY3fZ4s">To do so, we used generalized estimating equations for each behavioral factor (e.g., positive framing) with a log link and binary-distributed errors with optimal adherence, including all patient baseline characteristics but unadjusted for patient-level clustering due to sample size.</s><s xml:id="_E7SMzPu">Then, we described adherence to different behavioral factors based on the sequence of delivered text messages.</s><s xml:id="_yKK6aWp">Finally, patients were clustered by their average response to different text message factors using k-means clustering analysis, using a threshold of ≥25 responses; smaller numbers were replaced by average variable values.</s><s xml:id="_NsRVwVy">Using these clusters, we explored the bivariate association between key baseline patient demographic/clinical characteristics and membership in each group using multinomial logistic regression (Referent: Group 3).</s><s xml:id="_QyZZTdw">Together, these findings may provide a more accurate starting point for future programs.</s></p><p xml:id="_dtW7vTz"><s xml:id="_sj8hJDg">Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.</s><s xml:id="_dwFQetH">The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.</s><s xml:id="_Gtq9X32">If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_VfWysHr">To view a copy of this licence, visit <ref type="url" target="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 3 |</head><label>3</label><figDesc><div><p xml:id="_a3vjXb4"><s xml:id="_72qCkjN">Fig. 3 | Most influential feature interactions in the reinforcement learning algorithm.</s><s xml:id="_BgYV5G7">This figure shows the model weights from the feature importance score from the reinforcement learning algorithm, which indicates which features were more or less importance to the model.</s><s xml:id="_DkTHmCu">The weights above were the 20 most influential features, ranked from highest to lowest.</s><s xml:id="_ftXPxPE">Abbreviations: HbA1c, glycated hemoglobin A1c; SGLT2, sodium-glucose cotransporter-2.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 7 |</head><label>7</label><figDesc><div><p xml:id="_Tr52Yy4"><s xml:id="_PP3sp2X">Fig.7| Clusters of responsiveness to behavioral factors included in text messages.</s><s xml:id="_rtd9Bt7">Each color represents one of the three different patient groups identified from the exploratory k-means clustering analysis for the average pill bottle adherence measured over 6 months (primary outcome).</s><s xml:id="_WhxspKb">These groups include: (1) Group 1 (Orange, n = 9) was the most adherent in response to observed feedback ("history"), (2) Group 2 (Yellow, n = 4) was the most adherent in response to social reinforcement or observed feedback, and (3) Group 3 (Blue, n = 16) was equally adherent in response to all types of messages.</s><s xml:id="_2W2mg2c">The error bars show the standard error for the cluster based on the underlying sample size (i.e., a threshold of ≥25 observations was applied).</s></p></div></figDesc><graphic coords="7,237.26,369.86,324.00,260.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 |</head><label>1</label><figDesc><div><p xml:id="_YSeshk9"><s xml:id="_2feZSUh">Baseline characteristics of trial patients</s></p></div></figDesc><table><row><cell></cell><cell>Reinforcement</cell><cell cols="2">Control (n = 31) Absolute stan-</cell></row><row><cell></cell><cell>learning (n = 29)</cell><cell></cell><cell>dardized</cell></row><row><cell></cell><cell></cell><cell></cell><cell>differences</cell></row><row><cell>Age, mean (SD)</cell><cell>60.3 (11.4)</cell><cell>56.7 (12.9)</cell><cell>0.02</cell></row><row><cell>Female sex, n (%)</cell><cell>12 (41.4%)</cell><cell>14 (45.2%)</cell><cell>0.08</cell></row><row><cell>Race/ethnicity, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>17 (58.6%)</cell><cell>18 (58.1%)</cell><cell>0.01</cell></row><row><cell>Black or African</cell><cell>6 (20.7%)</cell><cell>8 (25.8%)</cell><cell>0.12</cell></row><row><cell>American</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Other (Hispanic/</cell><cell>6 (20.7%)</cell><cell>7 (22.6%)</cell><cell>0.05</cell></row><row><cell>Latino,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Asian, Other)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Education level, n (%)</cell><cell></cell><cell></cell></row><row><cell>High school</cell><cell>7 (24.1%)</cell><cell>5 (16.1%)</cell><cell>0.20</cell></row><row><cell>graduate</cell><cell></cell><cell></cell><cell></cell></row><row><cell>or below</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Some college/</cell><cell>22 (51.7%)</cell><cell>19 (61.3%)</cell><cell>0.19</cell></row><row><cell>college graduate</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Post-graduate</cell><cell>7 (24.1%)</cell><cell>7 (22.6%)</cell><cell>0.04</cell></row><row><cell>Married or part-</cell><cell>13 (44.8%)</cell><cell>17 (54.8%)</cell><cell>0.20</cell></row><row><cell>nered, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline HbA1c,</cell><cell>8.99 (1.39)</cell><cell>9.10 (1.47)</cell><cell>0.06</cell></row><row><cell>mean (SD)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;9, n (%)</cell><cell>17 (58.6%)</cell><cell>17 (54.8%)</cell><cell>0.08</cell></row><row><cell>≥9, n (%)</cell><cell>12 (41.4%)</cell><cell>14 (45.2%)</cell><cell>0.08</cell></row><row><cell cols="3">Diabetes medication use (self-reported), n (%)</cell><cell></cell></row><row><cell>&lt;4 years</cell><cell>10 (34.5%)</cell><cell>13 (41.9%)</cell><cell>0.15</cell></row><row><cell>≥4 years</cell><cell>19 (65.5%)</cell><cell>18 (58.1%)</cell><cell>0.15</cell></row><row><cell>3 or more unique</cell><cell>19 (65.5%)</cell><cell>16 (51.6%)</cell><cell>0.29</cell></row><row><cell>physicians, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Number of medications, n (%)</cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>20 (69.0%)</cell><cell>25 (80.6%)</cell><cell>0.27</cell></row><row><cell>≥2</cell><cell>9 (31.0%)</cell><cell>6 (19.4%)</cell><cell>0.27</cell></row><row><cell cols="4">Non-adherence (number of self-reported doses missed in prior 30 days), %</cell></row><row><cell>≤1</cell><cell>17 (58.6%)</cell><cell>17 (54.8%)</cell><cell>0.08</cell></row><row><cell>&gt;1</cell><cell>12 (41.4%)</cell><cell>14 (45.2%)</cell><cell>0.08</cell></row><row><cell>Automaticity a with</cell><cell>5 (17.2%)</cell><cell>10 (32.3%)</cell><cell>0.36</cell></row><row><cell>medication-tak-</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ing, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Full patient health</cell><cell>16 (55.2%)</cell><cell>15 (48.4%)</cell><cell>0.13</cell></row><row><cell>activation b</cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_8ww5mk9"><p><s xml:id="_nsDMDSS">This table shows the baseline characteristics of the 60 randomized patients to the trial.</s><s xml:id="_V9hS82g">SD Standard deviation, HbA1 glycated hemoglobin A1c. a Highest possible score based on the automaticity subscale of the self-report behavioral automaticity index.</s><s xml:id="_ev6hCmW">b Full patient activation based on the consumer health activation index.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 |</head><label>2</label><figDesc><div><p xml:id="_b8h897a"><s xml:id="_znyd8Tb">Adherence as a function of the behavioral factors included in the text messages among intervention patients</s></p></div></figDesc><table><row><cell>Reflective</cell></row><row><cell>Content</cell></row><row><cell>Social</cell></row><row><cell>History (Observed feedback)</cell></row><row><cell>Framing (Negative)</cell></row><row><cell>Framing (Positive)</cell></row></table><note xml:id="_mJzmZHy"><p>This table shows the average adherence on the day and the day after a text message with these factors was selected and sent to intervention arm patients.</p><p>SD Standard deviation.</p><p>a Average adherence is measured by pill bottles in the day of interest and averaged across patients.</p><p><s xml:id="_3uFXjxJ">https://doi.org/10.1038/s41746-024-01028-5</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3 |</head><label>3</label><figDesc><div><p xml:id="_eXXJTwB"><s xml:id="_vbs4sQ8">Relationship between baseline characteristics and membership in clusters of responsiveness to behavioral factors</s></p></div></figDesc><table><row><cell>Referent: Group 3</cell><cell>Odds Ratio</cell><cell>Odds Ratio (95% CI) for Group 2</cell></row><row><cell>Baseline Characteristic</cell><cell>(95% CI) for Group 1</cell><cell></cell></row><row><cell>Age: ≥65 years vs. &lt;65 years</cell><cell>0.80 (0.16-4.12)</cell><cell>0.33 (0.03-3.92)</cell></row><row><cell>Sex: Female vs. Male</cell><cell>1.33 (0.25-7.01)</cell><cell>1.67 (0.18-15.13)</cell></row><row><cell>Race/ethnicity: White vs. Non-White</cell><cell>0.23 (0.04-1.30)</cell><cell>1.36 (0.11-16.58)</cell></row><row><cell>Partner status: Married/partnered vs. other</cell><cell>7.70 (1.15-51.15) a</cell><cell>0.73 (0.06-8.92)</cell></row><row><cell>Diabetes control: baseline HbA1c &lt; 9% vs. ≥9%</cell><cell>0.19 (0.03-1.14)</cell><cell>Too small to compute</cell></row><row><cell>Diabetes medication use: ≥4 years vs. &lt;4 years</cell><cell>4.80 (0.48-48.46)</cell><cell>0.20 (0.02-2.39)</cell></row><row><cell>Number of medications: 1 vs. ≥2</cell><cell>2.10 (0.32-13.61)</cell><cell>1.80 (0.15-21.48)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_cwqQ2ak"><s xml:id="_eWnK79m">npj Digital Medicine | (2024) 7:39</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_RH4MBJE"><s xml:id="_u2bZzxq">© The Author(s) 2024 https://doi.org/10.1038/s41746-024-01028-5</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_T4rS2uC">Acknowledgements</head><p xml:id="_cRyfJJt"><s xml:id="_hGN8Qzb">Research reported in this publication was supported by the <rs type="funder">National Institute on Aging of the National Institutes of Health</rs> under Award Number <rs type="grantNumber">P30AG064199</rs> to BWH (N.K.C.</s><s xml:id="_ufT4C5M">PI).</s><s xml:id="_KXV5jAY">J.C.L. was supported by a career development grant (<rs type="grantNumber">K01HL141538</rs>) from the <rs type="funder">NIH</rs>.</s><s xml:id="_tJyD8T9">The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</s><s xml:id="_fagHFaw">The authors wish to thank the <rs type="institution">Digital Care Transformation team at BWH</rs>, the team responsible for managing Microsoft Dynamics 365 SMS Texting.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_BCJ46Zr">
					<idno type="grant-number">P30AG064199</idno>
				</org>
				<org type="funding" xml:id="_9hvwH7p">
					<idno type="grant-number">K01HL141538</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HgPzDPG">Data availability</head><p xml:id="_AuZaU9V"><s xml:id="_s3fshXK">De-identified data necessary to reproduce results reported here are posted on the Harvard Dataverse, an open access repository for research data, at <ref type="url" target="https://dataverse.harvard.edu/">https://dataverse.harvard.edu/</ref>.</s><s xml:id="_m94tUEu">Some additional data, specifically dates such as for example dates of medication use, will be available upon reasonable request and execution of appropriate data use agreements, because dates are Protected Health Information under 45 CFR §164.154(b).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_m3XYF6a">Code availability</head><p xml:id="_6CKKrvQ"><s xml:id="_MZmKXjk">Code necessary to reproduce results reported here are available in the Harvard Dataverse at <ref type="url" target="https://dataverse.harvard.edu/">https://dataverse.harvard.edu/</ref>.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_thNZuAW">Author contributions</head><p xml:id="_G78GRSh"><s xml:id="_CCVtvCW">All authors meet International Committee of Medical Journal Editors (ICMJE) criteria.</s><s xml:id="_f5jgJhS">JCL had overall responsibility for the trial design and drafted the trial protocol and manuscript.</s><s xml:id="_F2C9mCE">NKC is the co-principal investigator, had overall responsibility for the trial design and trial protocol, and helped draft the trial protocol and manuscript.</s><s xml:id="_4HG8TyB">EYT, PAK, MEM, LGB, CPF, ESS, KC, GB, KH, and NH contributed meaningfully to trial or intervention design and implementation as well as the manuscript.</s><s xml:id="_WqnWbaA">All authors contributed to the refinement of the study protocol and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hxnpD9d">Competing interests</head><p xml:id="_FV5bXkK"><s xml:id="_cmSURMH">At the time this study was conducted, E.Y.-T. was an employee of Microsoft.</s><s xml:id="_tvmpKCc">N.K.C. serves as a consultant to Veracity Healthcare Analytics and holds equity in RxAnte and DecipherHealth; unrelated to the current work, N.K.C. has also received unrestricted grant funding payable to Brigham and Women's Hospital from Humana.</s><s xml:id="_PBe8DSu">N.H. has received personal fees from Cerebral unrelated to the current work.</s><s xml:id="_D952uDj">The remainder of the authors report no conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sQsa7MY">Ethical approval</head><p xml:id="_JkKSb5z"><s xml:id="_AE7vWTk">The trial was approved by the institutional review board (IRB) of Mass General Brigham and registered with clinicaltrials.gov</s><s xml:id="_HNA3Bp7">(NCT04473326).</s><s xml:id="_Pdg5qpA">The authors were responsible for performing study analyses, writing the manuscript, substantive edits, and submitting final contents for publication.</s><s xml:id="_tAbeYzU">Patients were not blinded due to the nature of the interventions.</s><s xml:id="_ktqE4BY">No data monitoring committee was deemed necessary by the IRB.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_TtZ3vHu">Additional information</head><p xml:id="_ySD7PSQ"><s xml:id="_cbqRjha">Supplementary information The online version contains supplementary material available at <ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref>.</s></p><p xml:id="_EcZpQgh"><s xml:id="_FnQMPYE">Correspondence and requests for materials should be addressed to Julie C. Lauffenburger.</s></p><p xml:id="_g5PfYev"><s xml:id="_4Zy7AKG">Reprints and permissions information is available at <ref type="url" target="http://www.nature.com/reprints">http://www.nature.com/reprints</ref></s><s xml:id="_VjAkM6j">Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s><s xml:id="_DCYeqms"><ref type="url" target="https://doi.org/10.1038/s41746-024-01028-5">https://doi.org/10.1038/s41746-024-01028-5</ref></s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_pBMBUce">Text messaging and patient engagement in an increasingly mobile world</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_r9Bdh93">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="555" to="556" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. &amp; Choudhry, N. K. Text messaging and patient engagement in an increasingly mobile world. Circulation 133, 555-556 (2016).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_cGNVWNB">Glycemic targets: standards of care in diabetes-2023</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Elsayed</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc23-s006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7ZukwTz">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="97" to="S110" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">ElSayed, N. A. et al. Glycemic targets: standards of care in diabetes- 2023. Diabetes Care 46, S97-S110 (2023).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_fG32XKg">Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Elsayed</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc23-s009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NzAHWCK">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="140" to="S157" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">ElSayed, N. A. et al. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care 46, S140-S157 (2023).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_QTY6v69">Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hamine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gerth-Guyette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Faulx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ginsburg</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.3951</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AyXzKEt">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hamine, S., Gerth-Guyette, E., Faulx, D., Green, B. B. &amp; Ginsburg, A. S. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J. Med. Internet Res. 17, e52 (2015).</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_6wYrH5H">Use of mobile health technology in the prevention and management of diabetes mellitus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yingling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Powell-Wiley</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-024-01028-5</idno>
		<ptr target="https://doi.org/10.1038/s41746-024-01028-5" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_QFaX8JP">Curr. Cardiol. Rep</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">130</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hartz, J., Yingling, L. &amp; Powell-Wiley, T. M. Use of mobile health technology in the prevention and management of diabetes mellitus. Curr. Cardiol. Rep. 18, 130 (2016). https://doi.org/10.1038/s41746-024-01028-5</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Zm5MNp9">The effectiveness of text message-based self-management interventions for poorly-controlled diabetes: a systematic review</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pfaeffli Dale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maddison</surname></persName>
		</author>
		<idno type="DOI">10.1177/2055207617740315</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YF6C2GW">Digit. Health</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">2055207617740315</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dobson, R., Whittaker, R., Pfaeffli Dale, L. &amp; Maddison, R. The effectiveness of text message-based self-management interventions for poorly-controlled diabetes: a systematic review. Digit. Health 3, 2055207617740315 (2017).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_eSxyeaA">Affect, framing, and persuasian</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Keller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4syWNPq">J. Mark. Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="54" to="64" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Keller, P. A. Affect, framing, and persuasian. J. Mark. Res. 40, 54-64 (2003).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_ebvZ6sq">The framing effect in medical decision-making: a review of the literature</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gong</surname></persName>
		</author>
		<idno type="DOI">10.1080/13548506.2013.766352</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M6YygcN">Psychol. Health Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="645" to="653" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gong, J. et al. The framing effect in medical decision-making: a review of the literature. Psychol. Health Med. 18, 645-653 (2013).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_6PqvKxq">Letters designed with behavioural science increase influenza vaccination in Medicare beneficiaries</title>
		<author>
			<persName><forename type="first">D</forename><surname>Yokum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ghazinouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y9mFyeg">Nat. Hum. Behav</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="743" to="749" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yokum, D., Lauffenburger, J. C., Ghazinouri, R. &amp; Choudhry, N. K. Letters designed with behavioural science increase influenza vaccination in Medicare beneficiaries. Nat. Hum. Behav. 2, 743-749 (2018).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main" xml:id="_nU78JgZ">The Elaboration Likelihood Model of Persuasion</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Petty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Cacioppo</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1986">1986</date>
			<publisher>Springer Series in Social PsychologyL</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Petty R. E. &amp; Cacioppo J. T. The Elaboration Likelihood Model of Persuasion, (Springer Series in Social PsychologyL, 1986).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_7h4Ef6C">Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Thakkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6MHugUP">JAMA Intern. Med</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="340" to="349" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thakkar, J. et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern. Med. 176, 340-349 (2016).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_6T5dZVR">A randomized controlled trial of personalized text message reminders to promote medication adherence among HIVpositive adolescents and young adults</title>
		<author>
			<persName><forename type="first">R</forename><surname>Garofalo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KEf6BYV">AIDS Behav</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1049" to="1059" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garofalo, R. et al. A randomized controlled trial of personalized text message reminders to promote medication adherence among HIV- positive adolescents and young adults. AIDS Behav. 20, 1049-1059 (2016).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_4xtqpGz">Tailored mobile text messaging interventions targeting type 2 diabetes selfmanagement: a systematic review and a meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Courtney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Naylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Rhodes</surname></persName>
		</author>
		<idno type="DOI">10.1177/2055207619845279</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cFfqDWG">Digit. Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">2055207619845279</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sahin, C., Courtney, K. L., Naylor, P. J. &amp; Rhodes, R. E. Tailored mobile text messaging interventions targeting type 2 diabetes self- management: a systematic review and a meta-analysis. Digit. Health 5, 2055207619845279 (2019).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_rAkUEvG">Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: the STIC2IT cluster randomized clinical trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2018.3189</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7b5Gpe9">JAMA Intern. Med</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="1182" to="1189" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choudhry, N. K. et al. Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: the STIC2IT cluster randomized clinical trial. JAMA Intern. Med. 178, 1182-1189 (2018).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_GgVn67c">Rationale and design of the Study of a Telepharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2016.07.017</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5gVvKMP">Am. heart J</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="page" from="90" to="97" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choudhry, N. K. et al. Rationale and design of the Study of a Tele- pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. Am. heart J. 180, 90-97 (2016).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_umZyQvG">Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EkhXD3K">PloS one</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">214754</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. et al. Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial. PloS one 14, e0214754 (2019).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_QRUQcNn">A highly tailored text and voice messaging intervention to improve medication adherence in patients with either or both hypertension and Type 2 diabetes in a UK primary care setting: feasibility randomized controlled trial of clinical effectiveness</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kassavou</surname></persName>
		</author>
		<idno type="DOI">10.2196/16629</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AJu2AY2">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">16629</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kassavou, A. et al. A highly tailored text and voice messaging intervention to improve medication adherence in patients with either or both hypertension and Type 2 diabetes in a UK primary care setting: feasibility randomized controlled trial of clinical effectiveness. J. Med. Internet Res. 22, e16629 (2020).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_2Svu3vW">Effects of a tailored text messaging intervention among diverse adults with Type 2 diabetes: evidence from the 15-Month REACH randomized controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Nelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Znp8JMZ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="26" to="34" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nelson, L. A. et al. Effects of a tailored text messaging intervention among diverse adults with Type 2 diabetes: evidence from the 15- Month REACH randomized controlled trial. Diabetes Care 44, 26-34 (2021).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_JbxQGj7">Personalization strategies in digital mental health interventions: a systematic review and conceptual framework for depressive symptoms</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hornstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zantvoort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Lueken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Funk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hilbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qfrgYSm">Front. Digit. Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">1170002</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hornstein, S., Zantvoort, K., Lueken, U., Funk, B. &amp; Hilbert, K. Personalization strategies in digital mental health interventions: a systematic review and conceptual framework for depressive symptoms. Front. Digit. Health 5, 1170002 (2023).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_xHZqYQp">Personalized mobile technologies for lifestyle behavior change: a systematic review, meta-analysis, and metaregression</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Tong</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ypmed.2021.106532</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TcaxFK6">Prev. Med</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page">106532</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tong, H. L. et al. Personalized mobile technologies for lifestyle behavior change: a systematic review, meta-analysis, and meta- regression. Prev. Med. 148, 106532 (2021).</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_pvv5q6J">Designing Reinforcement Learning Algorithms for Digital Interventions: Pre-Implementation Guidelines</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Trella</surname></persName>
		</author>
		<idno type="DOI">10.3390/a15080255</idno>
		<ptr target="https://doi.org/10.3390/a15080255" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_G8wxUun">Algorithms</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<date type="published" when="2022-08">Aug 2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Trella A. L., et al. Designing Reinforcement Learning Algorithms for Digital Interventions: Pre-Implementation Guidelines. Algorithms. Aug 2022;15 https://doi.org/10.3390/a15080255.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_cEMDMzj">REinforcement learning to improve nonadherence for diabetes treatments by Optimising Response and Customising Engagement (REINFORCE): study protocol of a pragmatic randomised trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2021-052091</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SEsrD6y">BMJ open</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">52091</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. et al. REinforcement learning to improve non- adherence for diabetes treatments by Optimising Response and Customising Engagement (REINFORCE): study protocol of a pragmatic randomised trial. BMJ open 11, e052091 (2021).</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_W2wQTBz">Evaluating the performance of reinforcement learning algorithms</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chandak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Thomas</surname></persName>
		</author>
		<ptr target="https://proceedings.mlr.press/v119/jordan20a/jordan20a.pdf" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_uN3YqhK">Proc. Thirty-Seventh International Conference on Machine Learning</title>
		<meeting>Thirty-Seventh International Conference on Machine Learning</meeting>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jordan S. M., Chandak Y., Cohen D., ZHang M. &amp; Thomas P. S. Evaluating the performance of reinforcement learning algorithms. In Proc. Thirty-Seventh International Conference on Machine Learning. 2020 https://proceedings.mlr.press/v119/jordan20a/jordan20a.pdf.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_NvxXDtk">Encouraging physical activity in patients with diabetes: intervention using a reinforcement learning system</title>
		<author>
			<persName><forename type="first">E</forename><surname>Yom-Tov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uPRua9d">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">338</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yom-Tov, E. et al. Encouraging physical activity in patients with diabetes: intervention using a reinforcement learning system. J. Med. Internet Res. 19, e338 (2017).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_Cwxc3rX">The potential impact of intelligent systems for mobile health self-management support: Monte Carlo simulations of text message support for medication adherence</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Piette</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12160-014-9634-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a9pxv8T">Ann. Behav. Med</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="84" to="94" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Piette, J. D. et al. The potential impact of intelligent systems for mobile health self-management support: Monte Carlo simulations of text message support for medication adherence. Ann. Behav. Med. 49, 84-94 (2015).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_737eRmq">Reinforcement-learning-based robust controller design for continuous-time uncertain nonlinear systems subject to input constraints</title>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1109/tcyb.2015.2417170</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e6pyXkX">IEEE Trans. Cyber</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1372" to="1385" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu, D., Yang, X., Wang, D. &amp; Wei, Q. Reinforcement-learning-based robust controller design for continuous-time uncertain nonlinear systems subject to input constraints. IEEE Trans. Cyber. 45, 1372-1385 (2015).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_4Z36qhK">Encouraging physical activity in patients with diabetes through automatic personalized feedback via reinforcement learning improves glycemic control</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hochberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Kd2DMVC">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="59" to="e60" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hochberg, I. et al. Encouraging physical activity in patients with diabetes through automatic personalized feedback via reinforcement learning improves glycemic control. Diabetes Care 39, e59-e60 (2016).</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_XS85vYJ">Personalized HeartSteps: A Reinforcement Learning Algorithm for Optimizing Physical Activity</title>
		<author>
			<persName><forename type="first">P</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Greenewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klasnja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Murphy</surname></persName>
		</author>
		<idno type="DOI">10.1145/3381007</idno>
		<ptr target="https://doi.org/10.1145/3381007" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_X4MTadB">Proc ACM Interact Mob Wearable Ubiquitous Technol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<date type="published" when="2020-03">Mar 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liao P., Greenewald K., Klasnja P. &amp; Murphy S. Personalized HeartSteps: A Reinforcement Learning Algorithm for Optimizing Physical Activity. Proc ACM Interact Mob Wearable Ubiquitous Technol. Mar 2020;4 https://doi.org/10.1145/3381007.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_3sstWA6">Microrandomized trials: developing just-in-time adaptive interventions for better public health</title>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Deliu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chakraborty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rGhBkNd">Am. J. Public Health</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="60" to="69" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu, X., Deliu, N. &amp; Chakraborty, B. Microrandomized trials: developing just-in-time adaptive interventions for better public health. Am. J. Public Health 113, 60-69 (2023).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_XbcE9VV">Treatment of epilepsy via batch-mode reinforcement learning</title>
		<author>
			<persName><forename type="first">A</forename><surname>Guez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Vincent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Avoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pineau</surname></persName>
		</author>
		<ptr target="https://cdn.aaai.org/IAAI/2008/IAAI08-008.pdf" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_X6jxKNW">Proc. Twenty-Third AAAI Conference on Artificial Intelligence</title>
		<meeting>Twenty-Third AAAI Conference on Artificial Intelligence</meeting>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="page" from="1671" to="1678" />
		</imprint>
	</monogr>
	<note type="raw_reference">Guez, A., Vincent, R. D., Avoli, M. &amp; Pineau, J. Treatment of epilepsy via batch-mode reinforcement learning. In Proc. Twenty-Third AAAI Conference on Artificial Intelligence. 2008:1671-1678 https://cdn.aaai.org/IAAI/2008/IAAI08-008.pdf.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_EWjRkkC">Micro-randomized trials: an experimental design for developing just-in-time adaptive interventions</title>
		<author>
			<persName><forename type="first">P</forename><surname>Klasnja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hqGVaNC">Health Psychol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1220" to="1228" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klasnja, P. et al. Micro-randomized trials: an experimental design for developing just-in-time adaptive interventions. Health Psychol. 34, 1220-1228 (2015).</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_PgfCq4e">The artificial intelligence Clinician learns optimal treatment strategies for sepsis in intensive care</title>
		<author>
			<persName><forename type="first">M</forename><surname>Komorowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Celi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Badawi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Faisal</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-018-0213-5</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9MbkEd9">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1716" to="1720" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C. &amp; Faisal, A. A. The artificial intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat. Med. 24, 1716-1720 (2018).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_SMmurZ5">Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021</title>
		<author>
			<persName><forename type="first">Gbdd</forename><surname>Collaborators</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(23)01301-6</idno>
		<ptr target="https://doi.org/10.1016/S0140-6736(23)01301-6" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_se3tRev">Lancet</title>
		<imprint>
			<date type="published" when="2023-06">Jun 2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Collaborators GBDD. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. Jun 2023; https://doi.org/10.1016/S0140-6736(23)01301-6.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_md7djcn">Feature selection and importance of predictors of non-communicable diseases medication adherence from machine learning research perspectives</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kanyongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Ezugwu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.imu.2023.101232</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VYAhzsf">Inform. Med. Unlocked</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">101132</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kanyongo, W. &amp; Ezugwu, A. E. Feature selection and importance of predictors of non-communicable diseases medication adherence from machine learning research perspectives. Inform. Med. Unlocked. 38, 101132 (2023).</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_jHJg8Qg">Machine learning approaches to medication adherence amongst NCD patients: A systematic literature review</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kanyongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Ezugwu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7F5e63z">Inform. Med. Unlocked</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">101210</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kanyongo, W. &amp; Ezugwu, A. E. Machine learning approaches to medication adherence amongst NCD patients: A systematic literature review. Inform. Med. Unlocked. 38, 101210 (2023).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_Wu9sybq">Economic impact of medication non-adherence by disease groups: a systematic review</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Cutler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fernandez-Llimos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frommer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Benrimoj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Garcia-Cardenas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EN2ugv4">BMJ open</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">16982</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C. &amp; Garcia-Cardenas, V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ open 8, e016982 (2018).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_KY98nMt">The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bitton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">S</forename><surname>Matlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Swanton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Shrank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CzzcB3j">Am. J. Med</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">27</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bitton, A., Choudhry, N. K., Matlin, O. S., Swanton, K. &amp; Shrank, W. H. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am. J. Med. 126, 357 e7-357.e27 (2013).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_FsX5cuc">The impact of automated brief messages promoting lifestyle changes delivered via mobile devices to people with Type 2 diabetes: a systematic literature review and meta-analysis of controlled trials</title>
		<author>
			<persName><forename type="first">C</forename><surname>Arambepola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fwfRmu8">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">86</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Arambepola, C. et al. The impact of automated brief messages promoting lifestyle changes delivered via mobile devices to people with Type 2 diabetes: a systematic literature review and meta-analysis of controlled trials. J. Med. Internet Res. 18, e86 (2016).</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_HeSdE3K">Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-Text Adherence Support [StAR]): a single-blind, randomized trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bobrow</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.115.017530</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KmNzKVS">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="592" to="600" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bobrow, K. et al. Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-Text Adherence Support [StAR]): a single-blind, randomized trial. Circulation 133, 592-600 (2016).</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_aQkEAz2">The impact of text messaging on medication adherence and exercise among postmyocardial infarction patients: randomized controlled pilot trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Krumme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Choudhry</surname></persName>
		</author>
		<idno type="DOI">10.2196/mhealth.7144</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BbJfeeH">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">110</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pandey, A., Krumme, A., Patel, T. &amp; Choudhry, N. The impact of text messaging on medication adherence and exercise among postmyocardial infarction patients: randomized controlled pilot trial. JMIR Mhealth Uhealth 5, e110 (2017).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main" xml:id="_7AgKkUr">PopTherapy: coping with stress through pop-culture</title>
		<author>
			<persName><forename type="first">P G-Br</forename><surname>Paredes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Czerwinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roseway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hernandez</surname></persName>
		</author>
		<idno type="DOI">10.4108/icst.pervasivehealth.2014.255070</idno>
		<ptr target="https://doi.org/10.1038/s41746-024-01028-5" />
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="page" from="109" to="117" />
		</imprint>
	</monogr>
	<note type="raw_reference">Paredes P G-BR, Czerwinski M., Roseway A., Rowan K. &amp; Hernandez J. PopTherapy: coping with stress through pop-culture. 109-117 (2014) https://dl.acm.org/doi/10.4108/icst.pervasivehealth.2014.255070. https://doi.org/10.1038/s41746-024-01028-5</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_9J4UwPa">Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AyYSwcc">Am. heart J</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="36" to="43" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. et al. Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. Am. heart J. 228, 36-43 (2020).</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_NDQzWmV">Are caregivers adherent to their own medications?</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Shrank</surname></persName>
		</author>
		<idno type="DOI">10.1331/japha.2011.10006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZTpz22Y">J. Am. Pharmacists Assoc</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="492" to="498" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shrank, W. H. et al. Are caregivers adherent to their own medications? J. Am. Pharmacists Assoc 51, 492-498 (2011).</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_WrjCW4p">Comparison of pharmacy claims and electronic pill bottles for measurement of medication adherence among myocardial infarction patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mehta</surname></persName>
		</author>
		<idno type="DOI">10.1097/MLR.0000000000000950</idno>
		<ptr target="https://doi.org/10.1097/MLR.0000000000000950" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tst33Z4">Med. care</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Mehta S. J. et al. Comparison of pharmacy claims and electronic pill bottles for measurement of medication adherence among myocardial infarction patients. Med. care. https://doi.org/10.1097/MLR. 0000000000000950.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_Dbz4cWZ">Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Arnsten</surname></persName>
		</author>
		<idno type="DOI">10.1086/323201</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QMtgF8C">Clin. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1417" to="1423" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Arnsten, J. H. et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33, 1417-1423 (2001).</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_qV3jAdN">Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Franklin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W9QRQj2">Med. Care</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="789" to="796" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Franklin, J. M. et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med. Care 51, 789-796 (2013).</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_wxeNcJe">Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive TYPE 2 diabetes management algorithm -2018 executive summary</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Garber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TdKqY8K">Endocr. Pr</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="91" to="120" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garber, A. J. et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive TYPE 2 diabetes management algorithm -2018 executive summary. Endocr. Pr. 24, 91-120 (2018).</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_tBfZZFE">User experiences with a Type 2 diabetes coaching app: qualitative study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Baptista</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cFq7CWm">JMIR Diabetes</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">16692</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Baptista, S. et al. User experiences with a Type 2 diabetes coaching app: qualitative study. JMIR Diabetes 5, e16692 (2020).</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_h9VPTk2">mHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aguilera</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2019-034723corr1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NvaW7jy">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">34723</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aguilera, A. et al. mHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study. BMJ Open 10, e034723 (2020).</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_eqZcZsh">The REDCap consortium: building an international community of software platform partners</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Harris</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jbi.2019.103208</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SV39HXt">J. Biomed. Inf</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">103208</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inf. 95, 103208 (2019).</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_ccsfGpb">Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Harris</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jbi.2008.08.010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j4bJq2x">J. Biomed. Inf</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="377" to="381" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Harris, P. A. et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 42, 377-381 (2009).</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_abnAjKz">Development and validation of the consumer health activation index</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wolf</surname></persName>
		</author>
		<idno type="DOI">10.1177/0272989x17753392</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NkU9YZd">Med. Decis. Mak</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="334" to="343" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wolf, M. S. et al. Development and validation of the consumer health activation index. Med. Decis. Mak. 38, 334-343 (2018).</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_EHFbxtP">Towards parsimony in habit measurement: testing the convergent and predictive validity of an automaticity subscale of the Self-Report Habit Index</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>De Bruijn</surname></persName>
		</author>
		<idno type="DOI">10.1186/1479-5868-9-102</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jrNUbfK">Int. J. Behav. Nutr. Phys. Act</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">102</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gardner, B., Abraham, C., Lally, P. &amp; de Bruijn, G. J. Towards parsimony in habit measurement: testing the convergent and predictive validity of an automaticity subscale of the Self-Report Habit Index. Int. J. Behav. Nutr. Phys. Act. 9, 102 (2012).</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_ag8CSmP">Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the heartstrong randomized clinical trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Volpp</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2017.2449</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XBNv9fg">JAMA Intern. Med</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="1093" to="1101" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Volpp, K. G. et al. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the heartstrong randomized clinical trial. JAMA Intern. Med. 177, 1093-1101 (2017).</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_KERVSdV">Self-efficacy: toward a unifying theory of behavioral change</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bandura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hP2MWXN">Psychol. Rev</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="191" to="215" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bandura, A. Self-efficacy: toward a unifying theory of behavioral change. Psychol. Rev. 84, 191-215 (1977).</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_a77Nek3">A framework for the unification of the behavioral sciences</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gintis</surname></persName>
		</author>
		<idno type="DOI">10.1017/s0140525x07000581</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j8UvEHR">Behav. Brain Sci</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gintis, H. A framework for the unification of the behavioral sciences. Behav. Brain Sci. 30, 1-16 (2007).</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_jRFcQbs">Common methodological framework for theory construction and evaluation in the social and behavioral sciences</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">C</forename><surname>Tzeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nPKz3H7">Genet. Soc. Gen. Psychol. Monogr</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="49" to="76" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tzeng, O. C. &amp; Jackson, J. W. Common methodological framework for theory construction and evaluation in the social and behavioral sciences. Genet. Soc. Gen. Psychol. Monogr. 117, 49-76 (1991).</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_EaE44St">Preferences for mHealth technology and text messaging communication in patients with Type 2 diabetes: qualitative interview study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<idno type="DOI">10.2196/25958</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QWGEs5y">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">25958</biblScope>
			<date type="published" when="2021-06">2021. Jun</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. et al. Preferences for mHealth technology and text messaging communication in patients with Type 2 diabetes: qualitative interview study. J. Med. Internet Res. 23, e25958 (2021). Jun.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_sYmP3Dx">Social reinforcement effects as a function of social reinforcement history</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Baron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_93QSJwP">Psychol. Rev</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="527" to="539" />
			<date type="published" when="1966">1966</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Baron, R. M. Social reinforcement effects as a function of social reinforcement history. Psychol. Rev. 73, 527-539 (1966).</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_GCcpPRK">Quantifying social reinforcement among family members on adherence to medications for chronic conditions: a us-based retrospective cohort study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Choudhry</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11606-018-4654-9</idno>
		<ptr target="https://doi.org/10.1007/s11606-018-4654-9" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8Uu3CKm">J. General Intern. Med</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Lauffenburger J. C., Khan N. F., Brill G., Choudhry N. K. Quantifying social reinforcement among family members on adherence to medications for chronic conditions: a us-based retrospective cohort study. J. General Intern. Med. https://doi.org/10.1007/s11606-018-4654-9.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_a6QKTDv">Interventions to improve adherence to selfadministered medications for chronic diseases in the United States: a systematic review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Viswanathan</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-157-11-201212040-00538</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y7gE2k4">Ann. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="785" to="795" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Viswanathan, M. et al. Interventions to improve adherence to self- administered medications for chronic diseases in the United States: a systematic review. Ann. Intern. Med. 157, 785-795 (2012).</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_BsAQrFY">Tools for the precision medicine era: how to develop highly personalized treatment recommendations from cohort and registry data using Q-learning</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Krakow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wxu4tFz">Am. J. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="160" to="172" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krakow, E. F. et al. Tools for the precision medicine era: how to develop highly personalized treatment recommendations from cohort and registry data using Q-learning. Am. J. Epidemiol. 186, 160-172 (2017).</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_V6y4QBA">Interactive model building for Q-learning</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Laber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Linn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Stefanski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wayxu7f">Biometrika</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="831" to="847" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Laber, E. B., Linn, K. A. &amp; Stefanski, L. A. Interactive model building for Q-learning. Biometrika 101, 831-847 (2014).</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_dxNvMmN">Q-learning: a data analysis method for constructing adaptive interventions</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nahum-Shani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HMRKZFR">Psychol. Methods</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="478" to="494" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nahum-Shani, I. et al. Q-learning: a data analysis method for constructing adaptive interventions. Psychol. Methods 17, 478-494 (2012).</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_hnDZdkT">Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Austin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p9eu7p5">Stat. Med</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3083" to="3107" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083-3107 (2009).</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_2TkyCYD">Prevalence and impact of having multiple barriers to medication adherence in nonadherent patients with poorly controlled cardiometabolic disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lauffenburger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BMrBXYn">Am. J. Cardiol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="376" to="382" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lauffenburger, J. C. et al. Prevalence and impact of having multiple barriers to medication adherence in nonadherent patients with poorly controlled cardiometabolic disease. Am. J. Cardiol. 125, 376-382 (2020).</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_TatWrgp">Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework</title>
		<author>
			<persName><forename type="first">C</forename><surname>Easthall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bhattacharya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_56K7U3B">Int. J. Pharm. Pract</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="223" to="231" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Easthall, C., Taylor, N. &amp; Bhattacharya, D. Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int. J. Pharm. Pract. 27, 223-231 (2019).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
